FDNA™ is a pioneering company at the forefront of artificial intelligence-based phenotyping technologies, enhancing the way genetic information informs healthcare decisions. Established in 2011, FDNA focuses on integrating genomic analysis into clinical practices, making it a standard in diagnostic evaluations. With its innovative next-generation phenotyping (NGP) solutions, FDNA serves over 70% of the world’s geneticists across 2,000 clinical sites in over 130 countries.

Among its flagship products are Face2Gene™ and FDNA Health™, which leverage a vast database of phenotypic and genotypic data linked to more than 10,000 diseases, collated from real-world cases. This information is securely stored in a cloud-based clinical warehouse and seamlessly integrates with various healthcare systems via open APIs. By bridging advanced AI technology with clinical genetics, FDNA is committed to empowering clinicians, researchers, and laboratories globally in their quest to diagnose and treat genetic conditions effectively, improving outcomes for millions of patients living with genetic disorders.